| Oct 26 |
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
|
| Oct 25 |
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
|
| Oct 23 |
Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results
|
| Oct 15 |
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks
|
| Sep 30 |
Celldex started by Goldman Sachs at neutral, lack of catalysts cited
|
| Sep 26 |
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
|
| Sep 25 |
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
|
| Sep 25 |
Celldex stock tumbles 20% amid Phase 2 data release for barzolvolimab (update)
|
| Sep 25 |
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
|
| Sep 16 |
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
|
